Proven Performance 1

An active ingredient with over 30 years of clinical proof—the most prescribed retinoid of all time.2

Proven Technology3

Controlled-release advanced technology minimizes irritation.

Proven Satisfaction4

Patients are highly compliant and feel highly satisfied when the RETIN-A MICRO® Pump is a part of their acne regimen.*

*Seen at the conclusion of the 12-week P.U.M.P. study.

Indication Statement for applicable product

RETIN-A MICRO® (tretinoin gel) microsphere, 0.04% and 0.1% are indicated for topical application in the treatment of acne vulgaris.

Important Safety Information:

RETIN-A MICRO® (tretinoin gel) microsphere, 0.04% and 0.1% is contraindicated in individuals with a history of sensitivity reactions to any of its components. The skin of certain individuals may become excessively dry, red, swollen or blistered. If warranted, these individuals should temporarily reduce the amount or frequency of application, or discontinue use temporarily or all together. Patients should be encouraged to minimize exposure to sunlight, including sunlamps, and to use a sunscreen with a SPF of 15 or higher and protective clothing. The most common adverse reactions to RETIN-A MICRO 0.04% and 0.1% were limited to mild or moderate irritation of the skin. 1.3% of patients using RETIN-A MICRO 0.04% and 6% of patients using RETIN-A MICRO 0.1% discontinued due to irritation. RETIN-A MICRO 0.04% and 0.1% showed a visible reduction in total mean lesion count in as little as 2 weeks with full benefits seen after 7 weeks.

References:
1. Eichenfield LF, Nighland M, Rossi AB, et al; PUMP Study Group. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129-1136.
2. IMS Health, NPA 05/07.
3. Embil K, Nacht S. The Microsponge® Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul. 1996;13(5):575-588.
4. Data on file, Ortho Dermatologics.